- Home
- OCS vs IVA Comparison
OCS vs IVA Comparison
Compare OCS & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCS
- IVA
- Stock Information
- Founded
- OCS 2003
- IVA 2011
- Country
- OCS Switzerland
- IVA France
- Employees
- OCS N/A
- IVA N/A
- Industry
- OCS Biotechnology: Pharmaceutical Preparations
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- OCS Health Care
- IVA Health Care
- Exchange
- OCS Nasdaq
- IVA Nasdaq
- Market Cap
- OCS 956.4M
- IVA 769.0M
- IPO Year
- OCS N/A
- IVA 2020
- Fundamental
- Price
- OCS $17.34
- IVA $5.31
- Analyst Decision
- OCS Strong Buy
- IVA Strong Buy
- Analyst Count
- OCS 4
- IVA 6
- Target Price
- OCS $35.75
- IVA $15.33
- AVG Volume (30 Days)
- OCS 14.2K
- IVA 75.4K
- Earning Date
- OCS 11-06-2025
- IVA 09-26-2025
- Dividend Yield
- OCS N/A
- IVA N/A
- EPS Growth
- OCS N/A
- IVA N/A
- EPS
- OCS N/A
- IVA N/A
- Revenue
- OCS $960,668.00
- IVA $14,591,573.00
- Revenue This Year
- OCS $11.49
- IVA $80.35
- Revenue Next Year
- OCS $1,784.02
- IVA N/A
- P/E Ratio
- OCS N/A
- IVA N/A
- Revenue Growth
- OCS N/A
- IVA N/A
- 52 Week Low
- OCS $11.78
- IVA $1.53
- 52 Week High
- OCS $23.08
- IVA $6.50
- Technical
- Relative Strength Index (RSI)
- OCS 48.91
- IVA 55.57
- Support Level
- OCS $16.94
- IVA $5.21
- Resistance Level
- OCS $17.34
- IVA $5.78
- Average True Range (ATR)
- OCS 0.40
- IVA 0.38
- MACD
- OCS 0.08
- IVA -0.06
- Stochastic Oscillator
- OCS 73.35
- IVA 39.59
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.